Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Tax Provisions (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Tax Provisions for 17 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 129.41% to -$1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$29.2 million, a 848.72% decrease, with the full-year FY2025 number at -$29.2 million, down 868.42% from a year prior.
  • Tax Provisions was -$1.0 million for Q4 2025 at Myriad Genetics, down from $1.2 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $15.2 million in Q3 2021 to a low of -$35.9 million in Q4 2021.
  • A 5-year average of -$4.4 million and a median of -$500000.0 in 2024 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: skyrocketed 800.0% in 2024, then tumbled 29400.0% in 2025.
  • Myriad Genetics' Tax Provisions stood at -$35.9 million in 2021, then soared by 72.7% to -$9.8 million in 2022, then surged by 88.78% to -$1.1 million in 2023, then skyrocketed by 409.09% to $3.4 million in 2024, then tumbled by 129.41% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Tax Provisions are -$1.0 million (Q4 2025), $1.2 million (Q3 2025), and -$100000.0 (Q2 2025).